Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study

Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L,...

. 2002 ; 249 () : 1088-1097.

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, klinické zkoušky, fáze I, klinické zkoušky, fáze II, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12016587

Grantová podpora
NF6560 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online

NLK SpringerLink Journals od 1997-01-01 do 2009-04-30
ProQuest Central od 1997-04-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-04-01 do Před 1 rokem

Odkazy

Knihovny.cz E-zdroje

RATIONALE: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis ( MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. PATIENTS: Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. RESULTS: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (+/-7)% (95 % confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by > or = 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival was 74 (+/-12)% at 3 years being 66 (+/-23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (+/-13)%; p = 0.59. The probability of confirmed disease progression was 20 (+/-11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33 %. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. CONCLUSION: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.

Errata: J Neurol. 2002 Oct;249(10):1482.-- J Neurol. 2002 Nov;249(11):1619.. Samign, J [corrected to Samijn, J].

000      
00000naa a2200000 a 4500
001      
bmc12016587
003      
CZ-PrNML
005      
20120604154502.0
007      
ta
008      
120525s2002 gw f 000 0eng||
009      
AR
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Fassas, Athanasios S. $u George Papanicolaou General Hospital, Dpt. Hematology, 57010 Thessaloniki, Greece. hempap@otenet.gr
245    10
$a Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study / $c Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A, Samijn J; Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation)
500    __
$a Errata: J Neurol. 2002 Oct;249(10):1482.-- J Neurol. 2002 Nov;249(11):1619.. Samign, J [corrected to Samijn, J].
520    9_
$a RATIONALE: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis ( MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. PATIENTS: Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. RESULTS: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (+/-7)% (95 % confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by > or = 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival was 74 (+/-12)% at 3 years being 66 (+/-23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (+/-13)%; p = 0.59. The probability of confirmed disease progression was 20 (+/-11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33 %. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. CONCLUSION: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.
650    _2
$a dospělí $7 D000328
650    _2
$a transplantace kostní dřeně $x mortalita $x škodlivé účinky $7 D016026
650    _2
$a počet CD4 lymfocytů $7 D018791
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mobilizace hematopoetických kmenových buněk $x škodlivé účinky $7 D019650
650    _2
$a transplantace hematopoetických kmenových buněk $x mortalita $x škodlivé účinky $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chronicko-progresivní roztroušená skleróza $x imunologie $x mortalita $x terapie $7 D020528
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Passweg, J. R. $u Kantonsspital Basel, Switzerland
700    1_
$a Anagnostopoulos, A. $u George Papanicolaou General Hospital, Dpt. Hematology, 57010 Thessaloniki, Greece $7 gn_A_00005806
700    1_
$a Kazis, A. $u George Papanicolaou General Hospital, Dpt. Hematology, 57010 Thessaloniki, Greece
700    1_
$a Kozák, Tomáš, $d 1963- $7 xx0021767 $u Charles University Prague, Czech Republic
700    1_
$a Kubala Havrdová, Eva, $d 1955- $7 nlk19990073204 $u Charles University Prague, Czech Republic
700    1_
$a Carreras, E. $u Hospital Clinic, Barcelona, Spain
700    1_
$a Graus, F. $u Hospital Clinic, Barcelona, Spain
700    1_
$a Kashyap, A. $u City of Hope Medical Center, Duarte, CA, USA
700    1_
$a Openshaw, H. $u City of Hope Medical Center, Duarte, CA, USA
700    1_
$a Schipperus, M. $u University Hospital Rotterdam, the Netherlands
700    1_
$a Deconinck, E. $u Hopital J. Minjoz, Besancon, France
700    1_
$a Mancardi, G. $u Ospedale S. Martino, Genova, Italy
700    1_
$a Marmont, A. $u Ospedale S. Martino, Genova, Italy
700    1_
$a Hansz, J. $u Marcinkowski University, Poznan, Poland
700    1_
$a Rabusin, M. $u Instituto per l'Infanzia Trieste, Italy
700    1_
$a Zuazu Nagore, F. J. $u Hospital Vall d'Hebron, Barcelona, Spain
700    1_
$a Besalduch, J. $u Hospital Son Dureta, Palma de Mallorca, Spain
700    1_
$a Dentamaro, T. $u University Tor Vergata Roma, Italy
700    1_
$a Fouillard, L. $u Hopital St. Antoine, Paris, France
700    1_
$a Hertenstein, B. $u Hannover Medical University, Germany
700    1_
$a La Nasa, G. $u Ospedali Binaghi, Centro Sclerosi Multipla, University Of Cagliari, Italy
700    1_
$a Musso, M. $u Ospedale de Maddalena, Palermo, Italy
700    1_
$a Papineschi, F. $u Azienda Ospedaliera, Pisa Italy
700    1_
$a Rowe, J. M. $u Rambam Medical Center, Haifa Israel
700    1_
$a Saccardi, R. $u Azienda Ospedaliera Careggi, Firenze Italy
700    1_
$a Steck, A. $u Kantonsspital Basel, Switzerland
700    1_
$a Kappos, L. $u Kantonsspital Basel, Switzerland
700    1_
$a Gratwohl, A. $u Kantonsspital Basel, Switzerland
700    1_
$a Tyndall, A. $u Kantonsspital Basel, Switzerland
700    1_
$a Samijn, J.
773    0_
$t Journal of neurology $x 0340-5354 $g Roč. 249(2002), s. 1088-1097 $w MED00002835
910    __
$a ABA008 $y 2
990    __
$a 20120525164832 $b ABA008
991    __
$a 20120604154429 $b ABA008
999    __
$a ok $b bmc $g 910379 $s 773729
BAS    __
$a 3
BMC    __
$a 2002 $b 249 $d 1088-1097 $x MED00002835 $i 0340-5354 $m Journal of neurology $n J Neurol
GRA    __
$a NF6560 $p MZ0
LZP    __
$a 2012-05/lmbo

Najít záznam

Citační ukazatele

Možnosti archivace